Breaking News

Michael J. Fox on a Parkinson's 'game changer'

April 15, 2023
A portrait of actor Michael J. FoxCourtesy Mark Seliger

A Parkinson's 'game changer,' backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments

Research funded by the Michael J. Fox Foundation for Parkinson's Research has resulted in the clearest evidence yet that the presence of a particular misfolded protein can be used to determine if people have Parkinson's. It is an advance that may soon be used to develop better diagnostics and rapidly accelerate the search for treatments for the disease. Read more.

By Matthew Herper



A view of Sarepta's red-brick headquarters.Kristoffer Tripplaar/SIPA via AP

Exclusive: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened

Reviewers at the FDA were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to step in earlier this year. Read more.

By Adam Feuerstein and Jason Mast


Courtesy Ole Frøbert

Scientists, going on a bear hunt, find a potential way to treat deadly blood clots

Cardiologist Manuela Thienel believes hibernating bears may hold an answer to an ailment that kills up to 100,000 Americans every year. When humans are rendered immobile for weeks or months, they are at high risk for a potentially fatal blood clot called venous thromboembolism. Yet every year brown bears curl up for four to seven months and suffer no blood-congealing consequences. Read more.

By Jason Mast


More great reads from STAT this week


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Weekend Reads? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments